1. Home
  2. NTNX vs GH Comparison

NTNX vs GH Comparison

Compare NTNX & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nutanix Inc.

NTNX

Nutanix Inc.

HOLD

Current Price

$39.84

Market Cap

12.4B

Sector

Technology

ML Signal

HOLD

Logo Guardant Health Inc.

GH

Guardant Health Inc.

HOLD

Current Price

$103.10

Market Cap

13.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTNX
GH
Founded
2009
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.4B
13.3B
IPO Year
2015
2018

Fundamental Metrics

Financial Performance
Metric
NTNX
GH
Price
$39.84
$103.10
Analyst Decision
Buy
Strong Buy
Analyst Count
16
22
Target Price
$69.93
$103.82
AVG Volume (30 Days)
4.0M
1.8M
Earning Date
02-21-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
227.45
6.74
EPS
0.21
N/A
Revenue
$2,537,927,000.00
$982,021,000.00
Revenue This Year
$14.31
$29.73
Revenue Next Year
$13.96
$27.71
P/E Ratio
$196.90
N/A
Revenue Growth
18.11
32.88
52 Week Low
$35.39
$34.91
52 Week High
$83.36
$120.74

Technical Indicators

Market Signals
Indicator
NTNX
GH
Relative Strength Index (RSI) 40.89 54.13
Support Level $40.18 $104.90
Resistance Level $41.78 $110.46
Average True Range (ATR) 1.67 6.38
MACD 0.52 -0.05
Stochastic Oscillator 71.40 60.66

Price Performance

Historical Comparison
NTNX
GH

About NTNX Nutanix Inc.

Nutanix Inc is engaged in cloud software, offering organizations a single platform for running applications and managing data anywhere. Its Nutanix Cloud Platform is designed to enable organizations to build a hybrid multicloud infrastructure, providing a consistent cloud operating model with a single platform for running applications and managing data in core data centers, at the edge, and in public clouds, all while supporting a variety of hypervisors and container platforms. The company operates a single operating and reportable segment based on a subscription business model. It conducts business in the United States, Europe, the Middle East and Africa, Asia Pacific, and other Americas, with key revenue generated from the United States.

About GH Guardant Health Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Share on Social Networks: